| Customization: | Available |
|---|---|
| Powder: | Yes |
| Certification: | ISO 9001, FDA |
|
Still deciding? Get samples of US$ 15/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| product name | Baricitinib |
| CAS NO. | 1187594-09-7 |
| Specification | 99% |
| Appearance | White powder |
| packing | 1kg/bag,25kgs/drum |
| MOQ | 1KG |
Baricitinib is a selective JAK2 and JAK1 inhibitor, an off-white or white crystalline powder, odorless and tasteless, commonly used to treat moderately to severely active rheumatoid arthritis (RA) in adults.
Baricitinib is an oral inhibitor of JAK kinases 1 and 2, commonly used to treat moderately to severely active rheumatoid arthritis (RA) in adults. Baricitinib can reduce disease activity in patients with RA who have not previously used biological DMARDS drugs.
In February 2017, baricitinib was approved by the European Union for the treatment of adult patients with moderately to severely active RA who have insufficient relief or intolerance to one or more anti-rheumatic drugs (DMARDs), either alone or in combination with methotrexate. This is also the first JAK inhibitor approved by the European Union for the treatment of RA.
In July 2017, the Ministry of Health, Labor and Welfare of Japan approved baricitinib for the treatment of patients with RA (including prevention of joint structural damage) who have not responded well to existing standard therapies. Kuwait and Switzerland also approved the marketing of baricitinib in June 2017.
In June 2018, the U.S. FDA approved baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitor therapies.
| Item | Specification | Test result |
| Appearance | white powder | Conforms |
| Assay | 99% | Conforms |
| Heavy metal | ≤10ppm | Conforms |
| Lead | ≤2.0ppm | Conforms |
| As | ≤2.0ppm | Conforms |
| Ca | ≤1.0ppm | Conforms |
| Me | ≤0.1ppm | Conforms |
| Total aerobic microbial count | ≤1000CFU/g | Conforms |
| Total moulds&yeast count | ≤100CFU/g | Conforms |
| Enterobacterial | ≤10MPN/g | Conforms |
| Salmonella | N.D/25g | Conforms |
| Escherichia coli | N.D/10g | Conforms |
| Staphylococcus aureus | N.D/10g | Conforms |
| Pseudomonas aeruginosa | N.D/10g | Conforms |
| Conclusion: Conform with specification. | ||
Baricitinib is mainly used in the fields of medicine and scientific research. It is suitable for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. Patients who are intolerant to one or more anti-rheumatic drugs can use this product for treatment. This product can be used as a single drug or in combination with methotrexate. The efficacy of baricitinib in the treatment of psoriasis, diabetic nephropathy, atopic dermatitis, systemic lupus erythematosus and other diseases is in the Phase II clinical research stage.
){kind=link}